Follow this preprint
Feasibility of an Evolutionary Tumor Board for Generating Novel Personalized Therapeutic Strategies
View ORCID ProfileMark Robertson-Tessi, Joel S. Brown, Maria I. Poole, Matthew Johnson, View ORCID ProfileAndriy Marusyk, View ORCID ProfileJill A. Gallaher, View ORCID ProfileKimberly A. Luddy, Christopher J. Whelan, View ORCID ProfileJeffrey West, View ORCID ProfileMaximillian Strobl, View ORCID ProfileVirginia Turati, View ORCID ProfileHeiko Enderling, View ORCID ProfileMichael J. Schell, AikChoon Tan, Terry Boyle, Rikesh Makanji, Joaquim Farinhas, View ORCID ProfileHatem Soliman, Dawn Lemanne, View ORCID ProfileRobert A. Gatenby, View ORCID ProfileDamon R. Reed, View ORCID ProfileAlexander R. A. Anderson, Christine H. Chung
doi: https://doi.org/10.1101/2023.01.18.23284628
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Mark Robertson-Tessi
1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Joel S. Brown
1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Maria I. Poole
2Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Matthew Johnson
2Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Andriy Marusyk
3Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Jill A. Gallaher
1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Kimberly A. Luddy
1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Christopher J. Whelan
3Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Jeffrey West
1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Maximillian Strobl
1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Virginia Turati
1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Heiko Enderling
1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Michael J. Schell
4Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
AikChoon Tan
5Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Terry Boyle
6Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Rikesh Makanji
7Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Joaquim Farinhas
7Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Hatem Soliman
8Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Dawn Lemanne
9Oregon Integrative Oncology, Ashland, Oregon
10Department of Medicine, University of Arizona, Tucson, Arizona
Robert A. Gatenby
7Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Damon R. Reed
11Department of Individualized Cancer Management; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Alexander R. A. Anderson
1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Christine H. Chung
2Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Posted January 19, 2023.
Feasibility of an Evolutionary Tumor Board for Generating Novel Personalized Therapeutic Strategies
Mark Robertson-Tessi, Joel S. Brown, Maria I. Poole, Matthew Johnson, Andriy Marusyk, Jill A. Gallaher, Kimberly A. Luddy, Christopher J. Whelan, Jeffrey West, Maximillian Strobl, Virginia Turati, Heiko Enderling, Michael J. Schell, AikChoon Tan, Terry Boyle, Rikesh Makanji, Joaquim Farinhas, Hatem Soliman, Dawn Lemanne, Robert A. Gatenby, Damon R. Reed, Alexander R. A. Anderson, Christine H. Chung
medRxiv 2023.01.18.23284628; doi: https://doi.org/10.1101/2023.01.18.23284628
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Subject Areas
- Addiction Medicine (408)
- Allergy and Immunology (719)
- Anesthesia (214)
- Cardiovascular Medicine (3035)
- Dermatology (258)
- Emergency Medicine (456)
- Epidemiology (12959)
- Forensic Medicine (12)
- Gastroenterology (848)
- Genetic and Genomic Medicine (4770)
- Geriatric Medicine (440)
- Health Economics (747)
- Health Informatics (3026)
- Health Policy (1095)
- Hematology (405)
- HIV/AIDS (951)
- Medical Education (450)
- Medical Ethics (119)
- Nephrology (490)
- Neurology (4544)
- Nursing (242)
- Nutrition (671)
- Oncology (2361)
- Ophthalmology (666)
- Orthopedics (264)
- Otolaryngology (332)
- Pain Medicine (296)
- Palliative Medicine (85)
- Pathology (512)
- Pediatrics (1229)
- Primary Care Research (515)
- Public and Global Health (7131)
- Radiology and Imaging (1586)
- Respiratory Medicine (940)
- Rheumatology (456)
- Sports Medicine (396)
- Surgery (503)
- Toxicology (63)
- Transplantation (218)
- Urology (187)